Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in J apanese women aged 18–26 years
H Yoshikawa, K Ebihara, Y Tanaka, K Noda - Cancer science, 2013 - Wiley Online Library
A randomized double‐blind placebo‐controlled phase II trial was conducted to evaluate the
efficacy of a prophylactic quadrivalent vaccine targeting the human papillomavirus (HPV) …
efficacy of a prophylactic quadrivalent vaccine targeting the human papillomavirus (HPV) …
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12–24 in a Phase III …
MH Einstein, M Baron, MJ Levin, A Chatterjee… - Human …, 2011 - Taylor & Francis
In this observer-blind study (NCT00423046), women (N= 1,106), stratified by age (18–26, 27–
35, 36–45 years), were randomized (1: 1) to receive the HPV-16/18 vaccine (Cervarix® …
35, 36–45 years), were randomized (1: 1) to receive the HPV-16/18 vaccine (Cervarix® …
Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil®)
MAA Siddiqui, CM Perry - Drugs, 2006 - Springer
Abstract▴ Human papillomavirus (HPV) quadrivalent recombinant vaccine is a mixture of
virus-like particles derived from the L1 capsid proteins of HPV types 6, 11, 16 and 18. It is …
virus-like particles derived from the L1 capsid proteins of HPV types 6, 11, 16 and 18. It is …
Evaluation of bivalent human papillomavirus (HPV) vaccine safety and tolerability in a sample of 25 year old Tuscan women
The aim of this study was to gather data on the safety of the HPV-16/18 AS04-adjuvated
vaccine among women aged 25, evaluating the frequency and severity of adverse events …
vaccine among women aged 25, evaluating the frequency and severity of adverse events …
[HTML][HTML] Different dose series of human papillomavirus vaccine in young females: a pair-wise meta-analysis and network meta-analysis from randomized controlled …
L Kemin, Z Mengpei, Z Jing, Y Rutie - Frontiers in Public Health, 2023 - frontiersin.org
Objective To investigate the application value of different dose of HPV vaccine in young
females. Data sources The following databases were searched: Cochrane Library, PubMed …
females. Data sources The following databases were searched: Cochrane Library, PubMed …
Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional …
K Kavanagh, KG Pollock, K Cuschieri… - The Lancet infectious …, 2017 - thelancet.com
Summary Background On Sept 1, 2008, Scotland launched routine vaccination for human
papillomavirus (HPV) types 16 and 18, targeted at 12–13-year-old girls, of whom 92· 4 …
papillomavirus (HPV) types 16 and 18, targeted at 12–13-year-old girls, of whom 92· 4 …
[HTML][HTML] Ten years of human papillomavirus vaccination. From dermatology to oncology via infectology
FA Moraga-Llop - Anales de Pediatría (English Edition), 2018 - Elsevier
Human papillomavirus (HPV) was first identified in dermatology, and it was subsequently
demonstrated that is was required for the development of uterine cervical cancer and other …
demonstrated that is was required for the development of uterine cervical cancer and other …
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised …
N Muñoz, R Manalastas, P Pitisuttithum, D Tresukosol… - The Lancet, 2009 - thelancet.com
Background Although the peak incidence of human papillomavirus (HPV) infection occurs in
most populations within 5–10 years of first sexual experience, all women remain at risk for …
most populations within 5–10 years of first sexual experience, all women remain at risk for …
Argentina's successful implementation of a national human papillomavirus vaccination program
H Patel, E Wilson, C Vizzotti, G Parston, J Prestt… - Health …, 2016 - healthaffairs.org
Every year around fourteen million people globally are infected with human papillomavirus
(HPV), the sexually transmitted virus that is the cause of most cervical cancers. A number of …
(HPV), the sexually transmitted virus that is the cause of most cervical cancers. A number of …
[HTML][HTML] Effectiveness of a universal vaccination program with an HPV quadrivalent vaccine in young Brazilian women
EM Wendland, NL Kops, M Bessel, J Comerlato… - Vaccine, 2021 - Elsevier
We examined human papillomavirus (HPV) vaccine effectiveness in a nationwide sample of
women aged 16 to 25 years who utilized the public health system in Brazil. This was a cross …
women aged 16 to 25 years who utilized the public health system in Brazil. This was a cross …